GlassScriptPhysician profile
Dipa Avichal
NPI 1881074060
$7,073.73
in general payments reported to CMS, 2019-2025
34 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $386 · 2021: $1,053 · 2022: $1,521 · 2023: $1,286 · 2024: $780 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,893 · Education: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,892.61 |
| Education | $380.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $1,627.55 | 2020-2025 | Rayaldee |
| Pfizer INC. | $811.23 | 2019-2022 | |
| Amgen INC. | $667.04 | 2020-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $554.07 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $399.04 | 2022-2025 | |
| Corcept Therapeutics | $352.60 | 2021-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.73 | 2020-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $274.64 | 2020-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $234.94 | 2023-2025 | Freestyle Libre 3, Aveir, Mitraclip |
| Lilly USA, LLC | $230.29 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Vifor Pharma, INC. | $227.52 | 2020-2022 | |
| Abbvie INC. | $192.03 | 2021-2025 | Ubrelvy |
| Medtronic, INC. | $136.01 | 2023-2024 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $133.88 | 2021-2022 | |
| Mannkind Corporation | $127.99 | 2020-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $125.00 | 2024 | Omnipod |
| Amneal Pharmaceuticals LLC | $98.41 | 2023-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $93.10 | 2024-2025 | |
| Boston Scientific Corporation | $54.31 | 2025 | Watchman Flx |
| Kowa Pharmaceuticals America, INC. | $48.27 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $41.35 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $40.36 | 2021-2023 | Xarelto |
| Rhythm Pharmaceuticals, INC. | $37.90 | 2025 | Imcivree |
| Intuity Medical INC | $37.85 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ibsa Pharma INC. | $34.01 | 2021 | |
| Travere Therapeutics, INC. | $29.08 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $25.59 | 2025 | Yorvipath |
| Beta Bionics, INC. | $24.72 | 2024 | Ilet Bionic Pancreas |
| Madrigal Pharmaceuticals | $24.24 | 2025 | Rezdiffra |
| Lexicon Pharmaceuticals, INC. | $20.24 | 2024 | |
| Genzyme Corporation | $18.19 | 2023 | |
| Dynavax Technologies Corporation | $15.96 | 2025 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $14.52 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.07 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipa Avichal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.